SARS (severe acute respiratory syndrome) diagnosis and patenting, a story of two wars
This article was originally published in Clinica
Prompt diagnosis has emerged as the key priority of the war against severe acute respiratory syndrome (SARS), after mortality from the disease in China has soared to three times the World Health Organization's upgraded global rate of 7%. Meanwhile, manufacturers and public health bodies alike have become embroiled in a battle of their own to secure patenting rights over the virus.
You may also be interested in...
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.